Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
Acquisition diversifies durable cash flows and advances Zymeworks’ strategy to build a productive R&D company with a growing portfolio of revenue-generating assets YUPELRI® expected to contribute immediately accretive revenue and cash flow to Zymeworks with base case mid-teens IRR Zymeworks to retain existing commercial organization supporting YUPELRI hospital promotion The Company expects total revenue, including […]